New COVID treatment shows efficacy against omicron: Spain's PharmaMar

Published: Updated:
Enable Read mode
100% Font Size

Spain's PharmaMar said on Tuesday trials made in vitro and on animals showed its Plitidepsin drug had positive antiviral effects on the variants of COVID-19, including omicron.

The results of Phase I trials have shown the drug, also known as Aplidin, had a powerful antiviral activity against all the variants in vitro and a distribution into the lungs of animals tested, resulting in a 99 percent reduction of viral load in the lungs, the company said.


For more coronavirus news, visit our dedicated page.

The results of the trials were released in a paper published in the scientific journal Life Science Alliance, PharmaMar said.

The paper also reported positive effects of Phase I and II trials on patients.

"All data we have seen so far with Plitidepsin corroborate our initial hypothesis of its activity as antiviral," PharmaMar's Jose Maria Fernandez Sousa said in a statement.

The drug is being tested in final Phase III trials on patients.

Shares in PharmaMar rose 5.3 percent in early trading.

Plitidepsin is a drug developed by PharmaMar originally to treat cancer but has an effect as an antiviral.

Read more:

Bulgarian PM self-isolates after close COVID contact during security meeting

Poland’s total COVID-19 death toll passes 100,000 amid fourth wave

‘Deltacron’ likely result of lab error: Experts

Top Content Trending